Search Results

Deals

ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics

ERYTECH (Nasdaq & Euronext: ERYP) and PHERECYDES announce merger and name change to PHAXIAM Therapeutics, a clinical-stage biopharmaceutical company developing innovative extended bacteriophage therapies to target antimicrobial resistance (AMR).

June 26, 2023

·

7 min read

Deals

ERYTECH Provides Update on the Announced Combination with PHERECYDES

ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided anupdateon the announced combination with PHERECYDES.

May 15, 2023

·

9 min read

Genetown

ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes

ERYTECH Pharma announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger with Pherecydes at the Annual General Meeting on June 23.

June 5, 2023

·

1 min read

Genetown

ERYTECH announces that the Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma

ERYTECH Pharma, announced that the Lyon Commercial Court has rejected Akkadian’s request to postpone the vote on the merger with Pherecydes Pharma.

June 14, 2023

·

4 min read

Genetown

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023

ERYTECH Pharma announced the availability of the documents for its Annual General Meeting to be held on Friday, June 23, 2023.

May 24, 2023

·

2 min read

Business

ERYTECH Provides Business and Financial Update for the First Quarter of 2023

ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial updatefor thefirst quarter of 2023.

May 9, 2023

·

10 min read

Policy

ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market

ERYTECH Pharma dated April 12, 2023, to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

April 17, 2023

·

5 min read

Business

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022

ERYTECH Pharma (Nasdaq & Euronext: ERYP) today provided a business and financial update for the fourth quarter and full year of 2022.

March 22, 2023

·

11 min read

ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023

ERYTECH Pharma announced that all resolutions for which the Board of Directors recommended a vote in favor,including the approval of the merger with Pherecydes, were adopted by its shareholders at the Combined General Meeting that was held today, June 23, 2023

June 23, 2023

·

7 min read

Genetown

ERYTECH Provides Regulatory Update

ERYTECH Pharma provided a regulatory update, announcing that it is no longer seeking approval for Graspa® in hypersensitive acute lymphoblastic leukemia following feedback from the U.S. Food and Drug Administration.

August 24, 2022

·

6 min read